Literature DB >> 18606211

Fluoxetine potentiates GABAergic IPSCs in rat hippocampal neurons.

Zeng-You Ye1, Ke-Qing Zhou, Tian-Le Xu, Jiang-Ning Zhou.   

Abstract

The GABA system is highly involved in the pathophysiology of mood disorders such as depression. Altered GABAergic function is evident in depressed patients and animal models of depression. Currently, the most widely used antidepressants are selective 5-HT reuptake inhibitors, such as fluoxetine. However, the effects of fluoxetine on GABAergic synaptic neurotransmission remain poorly investigated. Whole-cell patch-clamp recordings from cultured rat hippocampal neurons were therefore conducted to investigate the effects of fluoxetine on GABAergic neurotransmission. The spontaneous inhibitory postsynaptic current (sIPSC) was completely blocked by 10 microM bicuculline and reversibly potentiated by 30 microM fluoxetine. The fluoxetine potentiation on either amplitude or frequency of sIPSCs was dose-dependent, with the EC(50) values of 10.96 and 14.26 microM, respectively. This potentiation was also TTX-insensitive, suggesting independence of presynaptic action potentials. The ritanserin (5 microM), a selective 5-HT(2) receptor antagonist, did not alter the fluoxetine potentiation on miniature inhibitory postsynaptic currents. Taken together, our data suggest that fluoxetine can potentiate GABAergic neurotransmission without depending on presynaptic firing of action potentials and its elevating of 5-HT receptor activities. This potentiation by fluoxetine may normalize the hippocampal GABA deficit during depression and in part exert its antidepressant activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18606211     DOI: 10.1016/j.neulet.2008.06.072

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  7 in total

1.  The GABAergic deficit hypothesis of major depressive disorder.

Authors:  B Luscher; Q Shen; N Sahir
Journal:  Mol Psychiatry       Date:  2010-11-16       Impact factor: 15.992

2.  Chronic curcumin treatment normalizes depression-like behaviors in mice with mononeuropathy: involvement of supraspinal serotonergic system and GABAA receptor.

Authors:  Xin Zhao; Chuang Wang; Jun-Fang Zhang; Li Liu; Ai-Ming Liu; Qing Ma; Wen-Hua Zhou; Ying Xu
Journal:  Psychopharmacology (Berl)       Date:  2013-12-03       Impact factor: 4.530

3.  The antidepressant fluoxetine mobilizes vesicles to the recycling pool of rat hippocampal synapses during high activity.

Authors:  Jasmin Jung; Kristina Loy; Eva-Maria Schilling; Mareike Röther; Jan M Brauner; Tobias Huth; Ursula Schlötzer-Schrehardt; Christian Alzheimer; Johannes Kornhuber; Oliver Welzel; Teja W Groemer
Journal:  Mol Neurobiol       Date:  2013-11-05       Impact factor: 5.590

4.  Development of micro-electrode array based tests for neurotoxicity: assessment of interlaboratory reproducibility with neuroactive chemicals.

Authors:  A Novellino; Bibiana Scelfo; T Palosaari; A Price; Tomasz Sobanski; T J Shafer; A F M Johnstone; G W Gross; A Gramowski; O Schroeder; K Jügelt; M Chiappalone; F Benfenati; S Martinoia; M T Tedesco; E Defranchi; P D'Angelo; M Whelan
Journal:  Front Neuroeng       Date:  2011-04-27

Review 5.  Altered γ-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressants.

Authors:  Alan L Pehrson; Connie Sanchez
Journal:  Drug Des Devel Ther       Date:  2015-01-19       Impact factor: 4.162

6.  SSRI and Motor Recovery in Stroke: Reestablishment of Inhibitory Neural Network Tonus.

Authors:  Camila B Pinto; Faddi G Saleh Velez; Fernanda Lopes; Polyana V de Toledo Piza; Laura Dipietro; Qing M Wang; Nicole L Mazwi; Erica C Camargo; Randie Black-Schaffer; Felipe Fregni
Journal:  Front Neurosci       Date:  2017-11-16       Impact factor: 4.677

7.  In silico Screening and Behavioral Validation of a Novel Peptide, LCGA-17, With Anxiolytic-Like Properties.

Authors:  Anton V Malyshev; Iuliia A Sukhanova; Alexander S Zlobin; Vasilina R Gedzun; Vsevolod V Pavshintsev; Ekaterina V Vasileva; Arthur O Zalevsky; Igor I Doronin; Nikita A Mitkin; Andrey V Golovin; Maxim L Lovat; Georgy I Kovalev; Yurii A Zolotarev; Askar R Kuchumov; Gennady A Babkin; Bernhard Luscher
Journal:  Front Neurosci       Date:  2021-08-02       Impact factor: 4.677

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.